



## Novel synthesis and $\gamma$ -alkylation reactions of 4-(1-pyrrolidinyl)-2(5*H*)-thiophenones


Yu-Jang Li,\* Zen-Ting Liu and Sheng-Chuan Yang

Department of Applied Chemistry, Chaoyang University of Technology, 168 Gifeng E. Rd, Wufeng, Taichung County, Taiwan 413, ROC

Received 16 February 2001; revised 11 September 2001; accepted 12 September 2001

**Abstract**—Four-step synthesis of achiral and chiral 4-(1-pyrrolidinyl)-2(5*H*)-thiophenones with 61 and 66% overall yields are described. The  $\gamma$ -alkylation reaction studies and synthetic applications toward the thiolactomycin analog are also reported. © 2001 Elsevier Science Ltd. All rights reserved.

Substituted thiotetronic acid related compounds such as (+)-thiolactomycin **1**,<sup>1</sup> thiotetromycin **2**,<sup>2</sup> and U-68,204 **3** are a group of compounds with important bioactivities.<sup>3</sup> For example, (+)-thiolactomycin **1** is an antibiotic produced by *Nocardia* sp. No. 2-200, that is active against many species of pathogens including Gram-positive cocci, enteric bacteria, acid-fast bacteria and anaerobic bacteria. It has been found that the combined use of thiolactomycin and  $\beta$ -lactam antibiotics produces a synergistic effect against the inducible  $\beta$ -lactamase-producing microorganism.<sup>4</sup> A common important feature in these three compounds is the  $\gamma$ -disubstitution on the thiotetronic acid. Therefore, the study of the  $\gamma$ -alkylation reaction of similar systems becomes vital to the synthesis of thiotetronic acid related antibiotics.<sup>5</sup>



Herein, we first report on a novel procedure for the synthesis of achiral and chiral 4-(1-pyrrolidinyl)-2(5*H*)-thiophenones.<sup>6</sup> Secondly,  $\gamma$ -alkylation reactions of the title compound has been studied and applied in the synthesis of a thiolactomycin analog.<sup>7</sup>

Methyl acetoacetate **4** in benzene was condensed with compound **5** or **5a** to afford vinylogous urethane **6** and


**6a** in 81 and 83% yields, respectively.<sup>8</sup> Deprotonation of **6** or **6a** with LDA, followed by chlorination with hexachloroethane afforded chlorinated compound **7** and **7a**, respectively. Subsequent treatment of the chlorinated compounds **7** or **7a** with potassium thioacetate produced thiolated adducts, which without purification were treated with sodium methoxide to facilitate cyclization to produce 2(5*H*)-thiophenones **8** and **8a** in 75 and 80% yields (Scheme 1).

With **8** and **8a** in hand, reaction of compound **8** was studied first under various conditions. Compound **8** was deprotonated with lithium diisopropylamide (LDA) and then treated with alkyl halide to produce mono-alkylated products **9–13** in moderate yields. A


second alkylation of **9** and **12**, using LDA or *t*-BuLi as a base, provided **14** and **15** in good yields (Scheme 2).

Deprotonation and alkylation of **8a** under similar conditions afforded **9a–13a** in 53–93% yields. Though the mono-alkylation reaction was successful in compound **8a**, di-alkylation of **8a** turned out to be problematic, presumably due to the steric hindrance of the bulky substitution on the pyrrolidine. The only success was the hydroxymethylation reaction. Deprotonation of **9a**

\* Corresponding author.



Scheme 1.




Scheme 2.

with *t*-BuLi followed by treatment with formaldehyde gas at  $-50^\circ\text{C}$  provided **16** in moderate yield and excellent diastereoselectivity (Scheme 3).

The diastereoselectivities of **9a–13a** and **16** were determined using HPLC and NMR as shown in Scheme 3. The stereochemistry of the major diastereomer as determined by single-crystal X-ray analysis of the compounds **9a** and **16** is shown in Fig. 1.<sup>9</sup>


Our synthetic approach toward the thiolactomycin analog started from the second alkylation of the compound **9**. Deprotonation of the compound **9**, followed by the addition–elimination reaction with a mixture (*E*:*Z*/3:1) of 3-bromo-2-methacrylonitrile provided **17E** and **17Z** in 81% yield with a 4:1 ratio.<sup>10</sup> Reduction of **17E** with diisobutylaluminum hydride (DIBAL-H) at  $-20^\circ\text{C}$  provided aldehyde **18** in 81% yield. Finally, reaction of compound **18** with phosphonium ylide generated by the deprotonation of methyltriphenylphosphonium iodide resulted in thiolactomycin analog **19** in 74% yield.<sup>11</sup> Synthetic efforts using chiral compound **9a**

Figure 1. Molecule structures of **9a** and **16**.


to synthesize the chiral analog are being continuously investigated in our laboratory (Scheme 4).

### Acknowledgements

We thank the National Science Council (NSC-87-2113-M-324-004) and Sinon cooperation for generous financial support. Partial support of the Mass spectrometer



Scheme 3.



**Scheme 4.** Reagents and conditions: (a) *t*-BuLi, THF, 3-bromo-2-methacrylonitrile (*E*:*Z*/3:1); (b) diisobutylaluminum hydride, heptane; (c) LDA, THF, methyltriphenylphosphonium iodide.

Facility provided by National Chung-Hsing University and the X-ray crystallography facility provided by National Taiwan University are also acknowledged.

## References

- Hasaki, H.; Oishi, H.; Hayashi, T.; Matsuura, I.; Ando, K.; Sawada, M. *J. Antibiot.* **1982**, *35*, 396–400.
- Omura, S.; Nakagawa, A.; Iwata, R.; Hatano, A. *J. Antibiot.* **1983**, *36*, 1781–1782.
- Dolak, L. A.; Castle, T. M.; Truesdell, S. E.; Sebek, O. K. *J. Antibiot.* **1986**, *39*, 26–31.
- Noto, T.; Miyakawa, S.; Oishi, H.; Endo, H.; Okazaki, H. *J. Antibiot.* **1982**, *35*, 401–410.
- For  $\gamma$ -alkylation reactions of thiotetronic acid system, see: (a) Wang, J. C.-L.; Salvino, J. M. *Tetrahedron Lett.* **1984**, *25*, 5243–5246; (b) Stachel, H.-D.; Fendl, A. *Arch. Pharm.* **1988**, *321*, 439–440.
- Synthesis and reaction studies of a similar furanone system has been reported previously by Professor R. H. Schlessinger in: (a) Schlessinger, R. H.; Iwanowicz, E. J. *Tetrahedron Lett.* **1988**, *29*, 1489; (b) Schlessinger, R. H.; Mjalli, A. M. M.; Adams, A. D. *J. Org. Chem.* **1992**, *57*, 2992.
- For synthesis related to thiolactomycin, see: Thomas, E. J.; Chambers, M. S. *J. Chem. Soc., Perkin Trans. 1* **1997**, 417–443 and references cited therein.
- For synthesis of **5a** see: Enders, D.; Kipphardt, H.; Gerdes, P.; Brena-Valle, L. J.; Bhushan, V. *Bull. Soc. Chim. Belg.* **1989**, *97*, 691–704.
- The crystal structure of compounds **9a** and **16** have been deposited at the Cambridge Crystallographic Data Centre as CCDC 158219 and CCDC 158220. The absolute stereochemistry at the  $\gamma$ -position was determined based on the existing chiral center on the pyrrolidine that originated from *L*-proline.
- For synthesis of 3-bromo-2-methacrylonitrile, see: Wiemer, D. F.; Han, Q. *J. Am. Chem. Soc.* **1992**, *114*, 7692–7697.
- All compounds have been fully characterized. **9**: mp 87–89°C.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  4.88 (s, 1H), 4.30 (q,  $J=6.96$  Hz, 1H), 3.50 (br, 2H), 3.29 (br, 2H), 1.85–2.18 (br, 4H), 1.66 (d,  $J=6.96$  Hz, 3H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  192.7, 172.9, 96.3, 50.6, 48.4, 43.8, 25.8(2C), 21.4. EIMS: 183 ( $\text{M}^+$ , 100), 150(80), 70 (80). Anal. calcd for  $\text{C}_9\text{H}_{13}\text{NOS}$ : C, 58.98; H, 7.15; N, 7.64. Found: C, 59.04; H, 7.29; N, 7.63. **9a**:  $[\alpha]_{\text{D}}^{20} = -49.6$  ( $c=1$ ,  $\text{CH}_2\text{Cl}_2$ ).  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  5.12 (s, 1H), 4.26 (q,  $J=6.87$  Hz, 1H), 3.59 (m, 1H), 3.49 (m, 2H), 3.10 (s, 3H), 1.99 (m, 4H), 1.60 (d,  $J=6.87$  Hz, 3H), 1.08 (s, 3H), 1.07 (s, 3H);  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  195.0, 175.4, 98.6, 78.7, 69.3, 49.8, 49.1, 44.4, 25.3, 24.3, 22.0(2C), 21.6. EIHRMS: ( $\text{C}_{13}\text{H}_{21}\text{NO}_2\text{S}$ ) calcd 255.1293; found 255.1295. Anal. calcd for  $\text{C}_{13}\text{H}_{21}\text{NO}_2\text{S}$ : C, 61.14; H, 8.29; N, 5.49; found C, 61.18; H, 8.26; N, 5.48. **17E**: mp 195–196°C.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  6.46 (s, 1H), 4.84 (s, 1H), 3.35 (br, 4H), 1.98 (br, 4H), 1.93 (s, 3H), 1.87 (s, 3H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  190.0, 171.2, 145.9, 119.7, 114.3, 96.8, 55.2, 50.5(2C), 29.5, 25.4(2C), 15.3. EIHRMS: ( $\text{C}_{13}\text{H}_{16}\text{N}_2\text{OS}$ ) calcd 248.0984; found 248.0991. **18**:  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  9.36 (s, 1H), 6.41 (s, 1H), 4.80 (s, 1H), 3.35 (br, 4H), 1.97 (br, 4H), 1.92 (s, 3H), 1.68 (s, 3H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  194.6, 194.2, 171.7, 151.1, 141.1, 97.2, 55.7, 50.8(2C), 29.2, 26.3(2C), 9.1. EIHRMS: ( $\text{C}_{13}\text{H}_{17}\text{NO}_2\text{S}$ ) calcd 251.0980; found 251.0979. **19**:  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  6.29 (dd,  $J=17.58$ , 10.84 Hz, 1H), 5.56 (d,  $J=17.58$  Hz, 1H), 5.05 (d,  $J=10.84$  Hz, 1H), 4.84 (s, 1H), 3.32 (br, 4H), 1.92 (br, 4H), 1.91 (s, 3H), 1.73 (s, 3H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  194.2, 174.7, 155.4, 140.51, 130.8, 113.7, 96.8, 56.3, 50.8(2C), 30.9, 26.3(2C), 11.6. EIHRMS: ( $\text{C}_{14}\text{H}_{19}\text{NOS}$ ) calcd 249.1187; found 249.1183.